Next Generation AAV Vectors
Inspired By Nature – Motivated by Health
At rAAVen Therapeutics, we combine rigorous science with curiosity-driven research to enable the next generation of gene therapies. Leveraging deep expertise in AAV biology, we design and engineer novel capsids to address a wide range of disorders across diverse tissues and organs. Using state-of-the-art methodologies in molecular cloning, high-throughput AAV variant production, and next-generation sequencing, we create viral vectors optimized for precision delivery to defined cell populations and tailored functional properties.
NEWS
As one of Europe’s leading spring biotech partnering events, BIO-Europe Spring is built around intensive one-to-one meetings that bring together biotech, pharma, and investors in a highly focused setting. It’s always a busy and productive few days, with packed schedules and valuable opportunities to start new conversations and strengthen existing relationships. If you’d like to meet with the rAAVen team during the event, please reach out directly or send us a request through the partnering platform.
November 03, 2025
CONTACT
We welcome inquiries from biotech and pharma teams interested in AAV capsid engineering, platform capabilities, or potential collaborations. Whether you are exploring a specific indication or want to understand how our rAAptr platform can support your gene therapy pipeline, we’re happy to discuss ideas at any stage. Reach out via email at info@raaven.se or through LinkedIn, and a member of the rAAVen team will get back to you.